Buradasınız

Anasayfa » Content

DÎABETÎK RAT MODELİNDE KISA SÜRELÎ DÜŞÜK MOLEKÜL AĞIRLIKLI HEPARIN TEDAVİSİNİN RENAL ETKÎLERÎ

RENAL EFFECTS OF SHORT TERM LOW MOLECULAR WEIGHT HEPARIN ADMINISTRATION IN DIABETIC RAT MODEL

Journal Name:

  • Türk Nefroloji, Diyaliz ve Transplantasyon Dergisi

Publication Year:

  • 1995

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Abnormal glycosaminoglycan metabolism is invol¬ved in the pathogenesis of diabetic nephropathy. Glo-merular membrane anionic charge depletion leading to albuminuria is associated with loss of glycosami-noglycan in urine. It's well known that long term ad¬ministration of different types of glycosaminoglycans prevents morphological renal alterations and albumi-nuria in diabetic rats. This study was designed to eva¬luate the effect of short term administration of nadro-parin calcium (a type of low molecular weight hepa-rin) on proteinuria and to measure heparan sulphate loss in the urine in a streptosotocin diabetic rat mo¬del. Twenty, twelve weeks old wistar rats were made diabetic using streptosotocin. One group of ten rats received nadroparin calcium 200 U/kgld, whilst the second group received. 0.1 cc saline/d as control. 24 hour urine samples were collected at the begining of the study and at the end of the 6th week for determi¬nation of creatinine clearence, heparan sulphate exc¬retion and microalbuminuria. Basal levels of microal-buminuria did not differ between nadroparin calcium and control groups (11 ± 13 mgld and 12.3 ±8 mgld respectively). At the end of the study microalbuminu-ria was significantly lower in the study group (2.8 ± 3.8 mgld and 28.5 ± 12 mgld respectively, p<0.05). Basal heparan sulphate excretion did not differ bet¬ween two groups (104.7 ± 66.5 [i^d and 128 ± 69.5 igld respectively). At the end of the study heparan sulphate excretion was significantly lower in the nadroparin calcium group (195 ± 96 mgld and 662 ±300 mgld respectively, p<0.01). In conclusion short term nadroparin calcium therapy may lead to reduction of microalbuminuria and heparan sulphate excretion by means of protection or replacement of the glomerular basement membrane anionic charge
Bookmark/Search this post with
Abstract (Original Language): 
Glukozaminoglikan metabolizma bozukluğu diabe-tik nefropati patogenezinde rol oynamakladır. Mikro-albüminüriye neden olan glomerüler bazal membran anyonik yük kaybı, idrarda glukozaminoglikan kaybı ile ilişkilidir. Diabetik rotlarda uzun süreli glukozaminoglikan tedavisinin hem morfolojik renal değişik¬likleri, hem de albüminüriyi önlediği bilinmektedir. Bu çalışma, kısa süreli nadroparin kalsiyum (düşük moleküler ağırlıklı heparin) tedavisinin renal fonksi¬yonlar, idrarda heparan sülfat ve albumin ekskresyo-nu üzerinde etkilerini araştırmak amacıyla planlan¬mıştır. Yirmi adet, oniki haftalık Wistar rat, strepto-zotosin ile diabetik hale getirilmiştir, on rattan olu¬şan birinci grup 200 U/kg/gün nadroparin kalsiyum tedavisi alırken, ikinci grupta kontrol olarak 0.1 cc serum fizyolojik verilmiştir. Hayvanların 24 saatlik kreatinin klirens, microalbüminüri ve heparan sülfat ekskresyonu ölçülmüştür. Nadroparin kalsiyum ve kontrol grupları arasında bazal mikroalbüminüri de¬ğerleri açısındanfark yoktur (11 ± 13 mglgün ve 12.3 ± 8 mglgün, sırasıyla). Çalışma sonunda tedavi gru¬bunda mikroalbüminüri kontrol grubuna oranla an¬lamlı ölçüde düşük bulunmuştur (2.8 ±3.8 mglgün ve 28.5 ± 12 mglgün sırasıyla, p<0.05). Çalışma baş¬langıcında heparan sülfat ekskresyonu her iki grup arasında farklılık göstermemekteyken (104.7 ± 66.5 [ig/gün ve 128 ± 69.5 [i-glgun, sırasıyla), tedavi so¬nunda nadroparin kalsiyum grubunda belirgin olarak düşük bulunmuştur (195 ± 96 [i-glgün ve 662 ± 300 [i^gun, sırasıyla, p<0.01). Sonuçta kısa süreli nadro-parin kalsiyum tedavisi idrarda heparan sülfat ve al-bümin ekskresyonunu belirgin olarak azaltmaktadır. Bu etki glomerül bazal membram anyonik yüklerinin korunması veya yerine konması ile ilişkili olabilir.
FULL TEXT (PDF): 
PDF icon pdf_tndt_84.pdf
  • 2
70-74
  • Turkish

REFERENCES

References: 

1. Andersen AR, Christiansen JS, Andersen JK. Kreiner S, Deckert T. Diabetic nephropathy in Type I (insulin dependent) diabetes: An epidemiologic study Dıabetolo-gia 1993; 25. 496-501.
2. Krolewsky AS- Warren JA, Chnstlieb AR, Busick ES-Kahn JR. The changing natural history of nephropathy in Type 1 diabetes. Am J Med 1985; 78: 785-794.
3. Ballarda DJ, Harping LL, et al. Epidemiology of persis-tant proteinuria in Type 2 diabetes mellitus. Diabetes
1988; 37: 405-412.
4. Mogensen CE. Microalbuminuria as a predictor of clini¬cal diabetic nepropathy. Kidney Tnt 1983; 31: 673-689.
5. Hostetter TH, Rennke HG, Brenner BM. The case for intrarenal hypertension in the inititiation and progressi¬on of diabetic and other glomerulopathy. Am J Med
1982; 72: 375-380.
6. Kverneland A, Feldt-Rasmussen B, Vidal P, et al. Evi¬dence of changes in renal selectivity in patients with type 1 (insulin dependent) diabetes mellitus. Diabetolo-
gia 1986; 29: 634-639.
7. Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jen¬sen T, Kofoed-Enevoldsen A. Albuminuria reflects wi¬despread vascular damage. The steno hypothesis. Diabe-
tologia 1988; 32: 219-226.
8. Colen MP, Klepser H, Wu VY. Undersulfation of glo-
merular basement membrane heparan sulfate in experi¬mental diabetes and lack of correction with aldose re-
ductase inhibition. Diabetes 1988; 37: 1324-1327.
9. Deckert T, Feldt-Rasmussen B, Djurup R, Deckert M. Glomerular size and charge selectivity in insulin depen¬dent diabetes mellitus. Kidney Int 1988; 33: 100-106.
10. Reddi AS. Glomerular and urinary glycosaminoglycans
in diabetic rats. Clinica Chimica Acta 1990; 189: 211¬220.
11. Gambaro G, Cavazza A, Luzi P, et al. Glycosaminogl-ycans prevent morphological renal alterations and albu-
minuria in diabetic rats. Kidney Int 1992; 42: 285-291.
12. Gambaro G, Venturi A, Noonvan DM, et al. Treatment with a glycosaminoglycan formulation ameloriates ex¬perimental diabetic nephrophaty. Kidney Int 1994; 46: 797-806.
13. Jong JGN, Wevers RA, Laarakkers C, Poorthuls JHM.
Dimethylmethylene bule based spectrophotometry of glycosaminoglycans in untreated urine: a rapid scree¬ning procedure for mucopolysaccharidosis. Clin Chem 1989; 35: 1472-1477.
14. Vora JP, Dolben J, Dean JD, et al. Renal hemodynamics in newly presenting non-insulin dependent diabetes mel-litus. Kidney Int 1992; 41: 829-835.
73
15. Rudberg S, Persson B, Dahlquist G. Increased glomerular filtration rate as a predictor of diabetic nephropathy: An 8 years prospective study. Kidney Int 1992; 41: 822¬835.
16. Baggio B. Briani G, Cicerello E, et al. Urinary glycosa-minoglycans, sialic acid and lysosomal enzymes increa¬se in nonaibuminuric diabetic patient. Nephron 1986; 43: 187-190.
17. Baggio B, Briani G, Cicerello E, Gambaro G; Borsatti A, et al. Urinary glycosaminoglycan excretion and mic-
roalbuminuria in diabetes. JAMA 1986; 255: 3250¬3251.
18. Deckert T, Feldt-Rasmussen B, Mathiesen E, Baker L. Pathogenesis of incipient nephropathy:a hypothesis. Di¬abetic Nephropathy 1985; 2: 83-88.
19. Rasch R, Mogensen CE. Urinary excretion of albumin and total protein in normal and streptosotocin diabetic
rats. Acta Endocrinol 1980; 95: 376-381.
20. Gambaro G, Venturini AP, Barbanti M, et al. Urinary excretion of glycoaminoglycans and albumin in experi¬mental diabetes. Contrib Nephrol 1993; 101: 109-113.
21. Wu VY, Wilson B, Cohen MP. Disturbances in glome-rular basement membrane glycosaminoglycans in expe¬rimental diabetes. Diabetes 1987; 36: 679-683.
22. Olson JL. Role of heparin as a protective agent follo¬wing reduction of renal mass. Kidney Int 1984; 25: 376¬382.
23. Castellot JJ, Hoover RL, Harper PA, Karnowsky MJ. Heparin and glomerular epithelial cell-secreted heparin like species inhibit mesangial cell proliferation. Am J
Pathol 1985; 120: 427-435.
24. Coffey AK, Karnowsky MJ. Heparin inhibits mesangial cell proliferation in Habuvenom-induced glomerular in¬jury. Am J Pathol 1985; 120: 248-255.
25. Diamond JR, Karnowsky MJ. Non-anticoagulant protec¬tive effect of heparin in chronic aminonucleoside neph-
rosis. Renal Physiol 1986; 9: 366-374.
26. Adler S, Eng B. Reversal of inhibition of rat glomerular epithelial cell growth by growth factors. Am J Pathol
1990; 136: 557-563.
27. Foidart JB, Pirard YS, Winnard RJ, Mahieu PR. Tissue
culture of normal rat glomeruli: Glycosaminoglycan bi¬osynthesis of homogeneous epithelial and mesangial cell
populations. Renal Physiol 1980; 3: 169-173.
74

Thank you for copying data from http://www.arastirmax.com